

US007029685B2

(12) United States Patent

Lanar et al.

(54) PLASMODIUM FALCIPARUM AMA-1 PROTEIN AND USES THEREOF

(75) Inventors: **David E. Lanar**, Takoma Park, MD (US); **Sheetij Dutta**, Silver Spring, MD (US); **Lisa A. Ware**, Silver Spring, MD (US); **Lalitha P. V. Nair**, New Delhi

(IN)

(73) Assignee: The United States of America as represented by the Secretary of the

Army, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 106 days.

(21) Appl. No.: 10/271,145

(22) Filed: Oct. 15, 2002

(65) **Prior Publication Data**

US 2003/0138450 A1 Jul. 24, 2003

Related U.S. Application Data

- (63) Continuation-in-part of application No. 10/105,717, filed on Mar. 25, 2002.
- (60) Provisional application No. 60/278,616, filed on Mar. 26, 2001.
- (51) **Int. Cl.**A61K 39/15 (2006.01)

 A61K 39/00 (2006.01)

(10) Patent No.: US 7,029,685 B2

(45) **Date of Patent:** Apr. 18, 2006

C07H 21/04 (2006.01) C12N 15/63 (2006.01) C12N 15/09 (2006.01)

(56) References Cited

U.S. PATENT DOCUMENTS

5,766,597 A 6/1998 Paoletti et al.

Primary Examiner—Lynette R. F. Smith Assistant Examiner—Padma Baskar (74) Attorney, Agent, or Firm—Elizabeth Arwine

(57) ABSTRACT

In this application is described the expression and purification of a recombinant *Plasmodium falciparum* (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.

20 Claims, 9 Drawing Sheets